Efgartigimod not checked

argenx · ARGX-113 · ARGX-113 PH20 SC

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
21 active
48 in total · 24 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Subcutaneous efgartigimod PH20 SC given by prefilled syringe”In the company’s words, NCT06558279 on ClinicalTrials.gov
Tested for
Generalized Myasthenia Gravis (5 trials), gMG (4 trials), Myasthenia Gravis (2 trials), Graves Disease (2 trials), AChR-Ab Seropositive Generalized Myasthenia Gravis (2 trials), New Onset Generalized Myasthenia Gravis (gMG), Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular and 26 more
Main trialPhase 4
“The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.”In the company’s words, NCT06909214 on ClinicalTrials.gov
Other names
ARGX-113 · ARGX-113 PH20 SC

Other drugs for Generalized Myasthenia Gravis

All 37 drugs for Generalized Myasthenia Gravis

Coming up12

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials48

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Aug 2026 A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
Phase 3Active, not recruiting 30 Jun 2025 A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Phase 3Active, not recruiting 12 Jan 2026 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Phase 3Active, not recruiting Jul 2027 A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
Phase 3Active, not recruiting Oct 2027 A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Phase 3Recruiting Jun 2028 A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Phase 3Recruiting Jun 2028 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Phase 3Recruiting Jun 2028 A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Phase 3Enrolling by invitation Sep 2028 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Phase 2/3Active, not recruiting Mar 2027 Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Phase 2/3Recruiting Sep 2027 A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Phase 2/3Recruiting Oct 2028 A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Phase 2/3Enrolling by invitation Sep 2029 Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Phase 2Active, not recruiting 30 Apr 2027 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Phase 2Recruiting Oct 2027 ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Phase 2Active, not recruiting Nov 2027 A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
Phase 2Recruiting 7 Mar 2028 ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Phase 2Not yet recruiting 28 Jul 2028 A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
Phase 2Not yet recruiting Jul 2030 A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
Phase 4Completed 19 Feb 2026 A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
Phase 3Completed 6 Apr 2020 An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Phase 3Completed 2 Nov 2021 Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
Phase 3Completed 3 Feb 2022 A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Phase 3Completed 23 Jun 2022 A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
Phase 3Completed 22 Aug 2023 A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
Phase 3Completed 24 Aug 2023 An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
Phase 3Completed 9 Oct 2023 A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Phase 3Terminated 25 Mar 2024 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
Phase 3Completed 31 Dec 2024 Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
Phase 3Terminated 20 Mar 2025 A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Phase 3Completed 11 Mar 2026 A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Phase 2/3Completed 13 Sep 2024 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Phase 2Completed 20 Oct 2017 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
Phase 2Completed 9 Apr 2019 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP
Phase 2Completed 29 Jan 2024 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)
Phase 2Completed 18 Apr 2024 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
Phase 2Terminated 5 Aug 2024 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
Phase 2Terminated 15 Aug 2024 Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS
Phase 2Completed 3 Feb 2025 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Phase 2Completed 2 Jul 2025 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)
Phase 1Completed 15 Nov 2016 IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
Phase 1Completed 24 Dec 2020 A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers
Phase 1Completed 8 Mar 2022 Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
Phase 1Completed 12 May 2023 A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults
Phase 1Completed 12 Jun 2024 A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod
Phase 1Completed 23 Sep 2026 A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants
Phase 2Authorised not given A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)
Phase 4Authorised not given Prospective experimental study to evaluate the efficacy and tolerability of efgartigimod as an early treatment in patients with generalised myasthenia gravis.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Efgartigimod

Following is part of Solo: you see every change to Efgartigimod the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in